NEW YORK (GenomeWeb) – ERS Genomics said today that it has licensed its CRISPR-Cas9 genome editing patents to the NMI Natural and Medical Sciences Institute at the University of Tübingen and its affiliate NMI TT Pharmaservices.

Under the terms of the non-exclusive licensing deal, NMI and NMI TT will gain access to the ERS patents in order to use them to expand their own custom cell-based research service offerings. Financial details of the agreement were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.